Ian Mark Bowen
Research Subjects
Research Interests
Ian Mark Bowen has a total of 121 co-authors. Here are the top co-authors by number of shared publications:
- Gayle Davina Hallowell
School of Veterinary Medicine and Science University of Nottingham Nottingham UK
14 shared publications - Celia M. Marr
Rossdales Equine Hospital Newmarket UK
7 shared publications R. Weller
Department of Farm Animal and Equine Medical Surgery, The Royal Veterinary College, University of London, Hatfield, Hertfordshire, UK
6 shared publications- Sarah Louise Freeman
School of Veterinary Medicine and Science University of Nottingham Leicestershire UK
5 shared publications - Adam Redpath
Donnington Grove Equine Hospital IVC Evidensia Malton UK
3 shared publications Celia M. Marr
3 shared publications
Latest Publications
- Open Access
- 19 August 2024
- Published by Wiley in Equine Veterinary Education
- Vol. 37 (2) , 90-97
Strangles vaccination: A current European perspective
Summary: Development of a subunit vaccine (Strangvac) from fusion of recombinant Streptococcus equi proteins offers a new tool in the management of infection with Streptococcus equi subspecies equi . Experience to date indicates that the vaccine is effective in limiting disease spread, and through inclusion of only the desired proteins needed for induction of an effective immune response, the safety profile appears far better than with previous vaccines. Published reports of the use of the vaccine are limited, and to date, vets have had limited information upon which to make informed decisions on the potential benefits of this novel vaccine. This article was developed to share the collective experience of the authors in using Strangvac and to highlight potential benefits of integrating vaccination alongside biosecurity measures in controlling ‘strangles’. This article reviews the use of vaccination prior to movement, in the face of outbreaks and also discusses use in mares and foals. Safety and the benefits of differentiating vaccinated from infected animals are also discussed. The reader should consider the level of evidence upon which the recommendations are based as it is frequently weak and limited to anecdotal reports or interpretation of unpublished data. The recommendations made are certain to be revised or replaced as new evidence comes forward but provide a basis for practitioners to implement vaccination strategies based on what is known currently. At times, the authors' recommendations deviate from those that were initially put down in the summary of product characteristics. This comes as a result of clinical experience that has been gained since the initial experimental studies were performed prior to registration. Veterinary surgeons using the vaccine outside of the regimen set down in the summary of product characteristics should be cognisant of their local legal framework and should ensure that they have informed consent to do so.
- 19 August 2024
- Published by Wiley in Equine Veterinary Education
- Vol. 37 (2) , 90-97
Open AccessStrangles vaccination: A current European perspective
Summary: Development of a subunit vaccine (Strangvac) from fusion of recombinant Streptococcus equi proteins offers a new tool in the management of infection with Streptococcus equi subspecies equi . Experience to date indicates that the vaccine is effective in limiting disease spread, and through inclusion of only the desired proteins needed for induction of an effective immune response, the safety profile appears far better than with previous vaccines. Published reports of the use of the vaccine are limited, and to date, vets have had limited information upon which to make informed decisions on the potential benefits of this novel vaccine. This article was developed to share the collective experience of the authors in using Strangvac and to highlight potential benefits of integrating vaccination alongside biosecurity measures in controlling ‘strangles’. This article reviews the use of vaccination prior to movement, in the face of outbreaks and also discusses use in mares and foals. Safety and the benefits of differentiating vaccinated from infected animals are also discussed. The reader should consider the level of evidence upon which the recommendations are based as it is frequently weak and limited to anecdotal reports or interpretation of unpublished data. The recommendations made are certain to be revised or replaced as new evidence comes forward but provide a basis for practitioners to implement vaccination strategies based on what is known currently. At times, the authors' recommendations deviate from those that were initially put down in the summary of product characteristics. This comes as a result of clinical experience that has been gained since the initial experimental studies were performed prior to registration. Veterinary surgeons using the vaccine outside of the regimen set down in the summary of product characteristics should be cognisant of their local legal framework and should ensure that they have informed consent to do so.
- Open Access
- 31 May 2024
- Published by Wiley in Veterinary Medicine and Science
- Vol. 10 (4) , e1448
Use of recombinant tissue plasminogen activator (rTPA) for treatment of fibrin in the anterior chamber of the horse
Background: Recombinant intracameral tissue plasminogen activator (rTPA) administration can aid clearance of fibrin from the anterior chamber.Materials and methods: In this retrospective multicentre case series, the effect of intracameral rTPA administration to treat fibrin in the anterior chamber resulting from trauma or inflammatory ocular disease was evaluated. Clinical data from 30 treatments in 29 horses were obtained from medical records from 2003 to 2022. Association between time from onset of clinical signs and time for rTPA treatment to effect was studied with regression analysis.Results: Twenty‐seven horses (93.1%) had no previous history of ophthalmic disease; one had an iridic cyst, and another had equine recurrent uveitis. The majority of cases were related to trauma (79.3%). Median time from the onset of clinical signs to treatment was 12 h (IQR = 4–48 h). rTPA (72% 20 µg; 24% 25 µg; 3.3% 40 µg) was administered once in all but one eye, which was treated twice. Resolution of fibrin was seen in 96.9% (29/30) of treatments. Fibrin accumulation recurred in one case but resolved 14 days after the second treatment. Complications were seen in four treatments (13.3%): moderate pain for 24 h, intracameral debris and mild intracameral haemorrhage in a horse that received 40 µg of tissue plasminogen activator. Recurrence of fibrin accumulation was absent in 96.7% of cases. Median time to effect was 20 min (IQR = 10–45 min). Time for rTPA treatment to effect was not associated with time from fibrin formation (R2 = 0.09; p = 0.11).Conclusion: Intracameral rTPA treatment can be considered at 20–25 µg in 0.1 mL solution to aid resolution of fibrin accumulation.
- 31 May 2024
- Published by Wiley in Veterinary Medicine and Science
- Vol. 10 (4) , e1448
Open AccessUse of recombinant tissue plasminogen activator (rTPA) for treatment of fibrin in the anterior chamber of the horse
Background: Recombinant intracameral tissue plasminogen activator (rTPA) administration can aid clearance of fibrin from the anterior chamber.Materials and methods: In this retrospective multicentre case series, the effect of intracameral rTPA administration to treat fibrin in the anterior chamber resulting from trauma or inflammatory ocular disease was evaluated. Clinical data from 30 treatments in 29 horses were obtained from medical records from 2003 to 2022. Association between time from onset of clinical signs and time for rTPA treatment to effect was studied with regression analysis.Results: Twenty‐seven horses (93.1%) had no previous history of ophthalmic disease; one had an iridic cyst, and another had equine recurrent uveitis. The majority of cases were related to trauma (79.3%). Median time from the onset of clinical signs to treatment was 12 h (IQR = 4–48 h). rTPA (72% 20 µg; 24% 25 µg; 3.3% 40 µg) was administered once in all but one eye, which was treated twice. Resolution of fibrin was seen in 96.9% (29/30) of treatments. Fibrin accumulation recurred in one case but resolved 14 days after the second treatment. Complications were seen in four treatments (13.3%): moderate pain for 24 h, intracameral debris and mild intracameral haemorrhage in a horse that received 40 µg of tissue plasminogen activator. Recurrence of fibrin accumulation was absent in 96.7% of cases. Median time to effect was 20 min (IQR = 10–45 min). Time for rTPA treatment to effect was not associated with time from fibrin formation (R2 = 0.09; p = 0.11).Conclusion: Intracameral rTPA treatment can be considered at 20–25 µg in 0.1 mL solution to aid resolution of fibrin accumulation.
- 7 March 2024
- Published by Wiley in Equine Veterinary Journal
- Vol. 56 (3) , 389-391
Less is more: Anthelmintic stewardship in an era of ubiquitous anthelmintic resistance and environmental sustainability
- 7 March 2024
- Published by Wiley in Equine Veterinary Journal
- Vol. 56 (3) , 389-391
Less is more: Anthelmintic stewardship in an era of ubiquitous anthelmintic resistance and environmental sustainability
- 2 January 2024
- Published by Wiley in Equine Veterinary Journal
- Vol. 56 (3) , 392-423
BEVA primary care clinical guidelines: Equine parasite control
Background: There is a lack of consensus on how best to balance our need to minimise the risk of parasite‐associated disease in the individual horse, with the need to limit the use of anthelmintics in the population to preserve their efficacy through delaying further development of resistance. Objectives: To develop evidence‐based guidelines utilising a modified GRADE framework. Methods: A panel of veterinary scientists with relevant expertise and experience was convened. Relevant research questions were identified and developed with associated search terms being defined. Evidence in the veterinary literature was evaluated using the GRADE evidence‐to‐decision framework. Literature searches were performed utilising CAB abstracts and PubMed. Where there was insufficient evidence to answer the research question the panel developed practical guidance based on their collective knowledge and experience. Results: Search results are presented, and recommendation or practical guidance were made in response to 37 clinically relevant questions relating to the use of anthelmintics in horses. Main limitations: There was insufficient evidence to answer many of the questions with any degree of certainty and practical guidance frequently had to be based upon extrapolation of relevant information and the panel members' collective experience and opinions. Conclusions: Equine parasite control practices and current recommendations have a weak evidence base. These guidelines highlight changes in equine parasite control that should be considered to reduce the threat of parasite‐associated disease and delay the development of further anthelmintic resistance.
- 2 January 2024
- Published by Wiley in Equine Veterinary Journal
- Vol. 56 (3) , 392-423
BEVA primary care clinical guidelines: Equine parasite control
Background: There is a lack of consensus on how best to balance our need to minimise the risk of parasite‐associated disease in the individual horse, with the need to limit the use of anthelmintics in the population to preserve their efficacy through delaying further development of resistance. Objectives: To develop evidence‐based guidelines utilising a modified GRADE framework. Methods: A panel of veterinary scientists with relevant expertise and experience was convened. Relevant research questions were identified and developed with associated search terms being defined. Evidence in the veterinary literature was evaluated using the GRADE evidence‐to‐decision framework. Literature searches were performed utilising CAB abstracts and PubMed. Where there was insufficient evidence to answer the research question the panel developed practical guidance based on their collective knowledge and experience. Results: Search results are presented, and recommendation or practical guidance were made in response to 37 clinically relevant questions relating to the use of anthelmintics in horses. Main limitations: There was insufficient evidence to answer many of the questions with any degree of certainty and practical guidance frequently had to be based upon extrapolation of relevant information and the panel members' collective experience and opinions. Conclusions: Equine parasite control practices and current recommendations have a weak evidence base. These guidelines highlight changes in equine parasite control that should be considered to reduce the threat of parasite‐associated disease and delay the development of further anthelmintic resistance.
- Open Access
- 4 November 2021
- Published by Wiley in Equine Veterinary Education
- Vol. 34 (7) , E268-E273
Unilateral degenerative joint disease of a cervical articular process joint between the fourth and fifth cervical vertebrae causing asymmetrical ataxia in a young horse
Summary: A 5‐year‐old horse was examined for investigation of asymmetrical, quadrilateral ataxia and paresis. Clinical examination was unremarkable, and a thorough neurological examination localised the lesion to the cervical spine. Following this, magnetic motor evoked potentials were acquired to allow for latency times to be determined. Abnormal conduction times were found to the right thoracic and right pelvic limbs, confirming that the horse had an asymmetrical cervical spinal myelopathy. Radiographs were acquired to ensure that the horse had no significant pathology which would contraindicate general anaesthesia. There were no abnormalities noted on these, so the horse underwent contrast‐enhanced computed tomography of its cervical spine which revealed enlargement of the right articular process joint between C4 and C5 with dorsolateral impingement of the spinal canal and cord. Due to the poor prognosis for future performance, the horse was subsequently euthanised. A post‐mortem examination confirmed the findings of degenerative joint disease, with some unexpected changes seen on histology of the spinal cord. The unilateral right‐sided compression had caused degenerative changes to ascending and descending tract bilaterally indicating a dynamic component to this lesion, which would be more commonly understood to be static.
- 4 November 2021
- Published by Wiley in Equine Veterinary Education
- Vol. 34 (7) , E268-E273
Open AccessUnilateral degenerative joint disease of a cervical articular process joint between the fourth and fifth cervical vertebrae causing asymmetrical ataxia in a young horse
Summary: A 5‐year‐old horse was examined for investigation of asymmetrical, quadrilateral ataxia and paresis. Clinical examination was unremarkable, and a thorough neurological examination localised the lesion to the cervical spine. Following this, magnetic motor evoked potentials were acquired to allow for latency times to be determined. Abnormal conduction times were found to the right thoracic and right pelvic limbs, confirming that the horse had an asymmetrical cervical spinal myelopathy. Radiographs were acquired to ensure that the horse had no significant pathology which would contraindicate general anaesthesia. There were no abnormalities noted on these, so the horse underwent contrast‐enhanced computed tomography of its cervical spine which revealed enlargement of the right articular process joint between C4 and C5 with dorsolateral impingement of the spinal canal and cord. Due to the poor prognosis for future performance, the horse was subsequently euthanised. A post‐mortem examination confirmed the findings of degenerative joint disease, with some unexpected changes seen on histology of the spinal cord. The unilateral right‐sided compression had caused degenerative changes to ascending and descending tract bilaterally indicating a dynamic component to this lesion, which would be more commonly understood to be static.
- Open Access
- 24 October 2020
- Published by Wiley in Veterinary Medicine and Science
- Vol. 7 (2) , 279-288
Use of aminoglycoside antibiotics in equine clinical practice; a questionnaire‐based study of current use
Veterinary use of the aminoglycoside antibiotics is under increasing scrutiny. This questionnaire‐based study aimed to document the use of aminoglycosides with a particular focus on gentamicin. An online questionnaire was delivered to generalist equine veterinary surgeons and specialists in internal medicine to determine the perceived importance, frequency of use and routes of administration of the aminoglycoside antibiotics. A series of hypothetical scenarios were also evaluated regarding gentamicin. Data were compared to evaluate the impact of the level of specialisation on prescribing practices for different antibiotics using Chi‐squared and Fischer's exact tests. Data were analysed from 111 responses. Gentamicin was commonly used empirically without culture and susceptibility testing. Generalists were more likely to use gentamicin only after susceptibility testing than specialists in a variety of clinical presentations including respiratory diseases, septic peritonitis, acute febrile diarrhoea, cellulitis and contaminated limb wounds (p < 0.01). Intravenous administration of gentamicin was most common, although inhaled and regional administration of gentamicin and amikacin were also described. Amikacin was most commonly used by intra‐articular administration. Gentamicin was more likely to be used in high‐risk procedures or contaminated surgeries (86% and 74%, respectively) compared with clean surgery (32%;p < 0.0001). Gentamicin was often used perioperatively in horses undergoing exploratory celiotomy and more commonly used in horses undergoing an enterotomy (90%) than without and enterotomy (79%;p = 0.04). Most respondents (86%) used gentamicin at a dose of 6.6 mg/kg in adults, with few changing their dosing strategies based on the presence of sepsis, although higher doses were more reported in foals (7–15 mg/kg) irrespective of the presence of sepsis. Aminoglycosides are widely used in equine practice and use outside current EU marketing authorisations is common. Stewardship of the aminoglycoside antibiotics could be enhanced in both generalists and specialists through the more frequent use of susceptibility testing, regional administration and dose adjustment, especially in foals.
- 24 October 2020
- Published by Wiley in Veterinary Medicine and Science
- Vol. 7 (2) , 279-288
Open AccessUse of aminoglycoside antibiotics in equine clinical practice; a questionnaire‐based study of current use
Veterinary use of the aminoglycoside antibiotics is under increasing scrutiny. This questionnaire‐based study aimed to document the use of aminoglycosides with a particular focus on gentamicin. An online questionnaire was delivered to generalist equine veterinary surgeons and specialists in internal medicine to determine the perceived importance, frequency of use and routes of administration of the aminoglycoside antibiotics. A series of hypothetical scenarios were also evaluated regarding gentamicin. Data were compared to evaluate the impact of the level of specialisation on prescribing practices for different antibiotics using Chi‐squared and Fischer's exact tests. Data were analysed from 111 responses. Gentamicin was commonly used empirically without culture and susceptibility testing. Generalists were more likely to use gentamicin only after susceptibility testing than specialists in a variety of clinical presentations including respiratory diseases, septic peritonitis, acute febrile diarrhoea, cellulitis and contaminated limb wounds (p < 0.01). Intravenous administration of gentamicin was most common, although inhaled and regional administration of gentamicin and amikacin were also described. Amikacin was most commonly used by intra‐articular administration. Gentamicin was more likely to be used in high‐risk procedures or contaminated surgeries (86% and 74%, respectively) compared with clean surgery (32%;p < 0.0001). Gentamicin was often used perioperatively in horses undergoing exploratory celiotomy and more commonly used in horses undergoing an enterotomy (90%) than without and enterotomy (79%;p = 0.04). Most respondents (86%) used gentamicin at a dose of 6.6 mg/kg in adults, with few changing their dosing strategies based on the presence of sepsis, although higher doses were more reported in foals (7–15 mg/kg) irrespective of the presence of sepsis. Aminoglycosides are widely used in equine practice and use outside current EU marketing authorisations is common. Stewardship of the aminoglycoside antibiotics could be enhanced in both generalists and specialists through the more frequent use of susceptibility testing, regional administration and dose adjustment, especially in foals.
- 28 October 2019
- Published by Wiley in Equine Veterinary Journal
- Vol. 52 (1) , 13-27
BEVA primary care clinical guidelines: Analgesia
Summary: Primary care guidelines provide a reference point to guide clinicians based on a systematic review of the literature, contextualised by expert clinical opinion. These guidelines develop a modification of the GRADE framework for assessment of research evidence (vetGRADE) and applied this to a range of clinical scenarios regarding use of analgesic agents. Key guidelines produced by the panel included recommendations that horses undergoing routine castration should receive intratesticular local anaesthesia irrespective of methods adopted and that horses should receive NSAIDs prior to surgery (overall certainty levels high). Butorphanol and buprenorphine should not be considered appropriate as sole analgesic for such procedures (high certainty). The panel recommend the continuation of analgesia for 3 days following castration (moderate certainty) and conclude that phenylbutazone provided superior analgesia to meloxicam and firocoxib for hoof pain/laminitis (moderate certainty), but that enhanced efficacy has not been demonstrated for joint pain. In horses with colic, flunixin and firocoxib are considered to provide more effective analgesia than meloxicam or phenylbutazone (moderate certainty). Given the risk of adverse events of all classes of analgesic, these agents should be used only under the control of a veterinary surgeon who has fully evaluated a horse and developed a therapeutic, analgesic plan that includes ongoing monitoring for such adverse events such as the development of right dorsal colitis with all classes of NSAID and spontaneous locomotor activity and potentially ileus with opiates. Finally, the panel call for the development of a single properly validated composite pain score for horses to allow accurate comparisons between medications in a robust manner.
- 28 October 2019
- Published by Wiley in Equine Veterinary Journal
- Vol. 52 (1) , 13-27
BEVA primary care clinical guidelines: Analgesia
Summary: Primary care guidelines provide a reference point to guide clinicians based on a systematic review of the literature, contextualised by expert clinical opinion. These guidelines develop a modification of the GRADE framework for assessment of research evidence (vetGRADE) and applied this to a range of clinical scenarios regarding use of analgesic agents. Key guidelines produced by the panel included recommendations that horses undergoing routine castration should receive intratesticular local anaesthesia irrespective of methods adopted and that horses should receive NSAIDs prior to surgery (overall certainty levels high). Butorphanol and buprenorphine should not be considered appropriate as sole analgesic for such procedures (high certainty). The panel recommend the continuation of analgesia for 3 days following castration (moderate certainty) and conclude that phenylbutazone provided superior analgesia to meloxicam and firocoxib for hoof pain/laminitis (moderate certainty), but that enhanced efficacy has not been demonstrated for joint pain. In horses with colic, flunixin and firocoxib are considered to provide more effective analgesia than meloxicam or phenylbutazone (moderate certainty). Given the risk of adverse events of all classes of analgesic, these agents should be used only under the control of a veterinary surgeon who has fully evaluated a horse and developed a therapeutic, analgesic plan that includes ongoing monitoring for such adverse events such as the development of right dorsal colitis with all classes of NSAID and spontaneous locomotor activity and potentially ileus with opiates. Finally, the panel call for the development of a single properly validated composite pain score for horses to allow accurate comparisons between medications in a robust manner.
- 2 September 2019
- Published by Mark Allen Group in UK-Vet Equine
- Vol. 3 (5) , 162-167
Embracing the Cascade: evidence-based medicine
The prescribing cascade is a risk-based algorithm that is applied on a case-by-case basis when selecting medicines that are not authorised in a given clinical scenario. It allows for the use of other veterinary medicines, whether authorised in the horse or other species, the use of human medicines from the UK and veterinary medicines from the EU or the use of specials (compounded or medicines produced extemporaneously). Its application brings with it several professional obligations and responsibilities, including the need to obtain written consent. Given the potential food-producing status of the horse, equine veterinary surgeons have additional considerations compared to those working with other species (whether farm animal or companion). Medicine selection under the Cascade must be based on valid justifications for not using authorised medicines (where available) and for the selection of subsequent steps in the Cascade. These justifications should be based on clinical need and a robust evidence base. Given that the Cascade exists to improve animal welfare, cost should not normally be considered as a reason for selecting medicines in the horse.
- 2 September 2019
- Published by Mark Allen Group in UK-Vet Equine
- Vol. 3 (5) , 162-167
Embracing the Cascade: evidence-based medicine
The prescribing cascade is a risk-based algorithm that is applied on a case-by-case basis when selecting medicines that are not authorised in a given clinical scenario. It allows for the use of other veterinary medicines, whether authorised in the horse or other species, the use of human medicines from the UK and veterinary medicines from the EU or the use of specials (compounded or medicines produced extemporaneously). Its application brings with it several professional obligations and responsibilities, including the need to obtain written consent. Given the potential food-producing status of the horse, equine veterinary surgeons have additional considerations compared to those working with other species (whether farm animal or companion). Medicine selection under the Cascade must be based on valid justifications for not using authorised medicines (where available) and for the selection of subsequent steps in the Cascade. These justifications should be based on clinical need and a robust evidence base. Given that the Cascade exists to improve animal welfare, cost should not normally be considered as a reason for selecting medicines in the horse.
- 26 February 2019
- Published by Wiley in Equine Veterinary Journal
- Vol. 51 (5) , 575-580
Misoprostol is superior to combined omeprazole‐sucralfate for the treatment of equine gastric glandular disease
Background Previous studies have demonstrated a poor response to healing of gastric glandular lesions with oral omeprazole and other medications. Objectives To evaluate the efficacy of two novel treatments (misoprostol [M] and combined omeprazole‐sucralfate [OS]) in the horse for gastric glandular disease. Study design Prospective, clinical study. Methods Sixty‐three sports horses with grade >1/4 glandular disease were identified by gastroscopy. Horses received either 5 μg/kg of misoprostol per os BID one hour prior to feeding or a combination of 4 mg/kg enteric coated omeprazole per os SID and 12 mg/kg sucralfate per os BID where drugs were given one hour prior to feeding and sucralfate given 60 minutes after omeprazole; allocation was dependent upon centre. Gastroscopy was repeated at 28‐35 days. Evaluators of the gastroscopy images were blinded to the treatments the horses received and images were reviewed independently. Results The most common presenting sign in both treatment groups was poor performance (Overall – 65.1%; M – 60.5% and OS – 75%). Overall healing (p<0.001; OR = 11 [2.8‐45]) and improvement (p = 0.006; OR = 11 [1.9‐59]) of lesions was associated with resolution of clinical signs. Misoprostol was shown to be superior to combined omeprazole‐sucralfate both for healing (M‐72% [95%CI–43‐67] and OS–20% [95% CI – 7‐41]; p<0.001) and improvement (M‐98% [95%CI–90‐100] and OS–65% [95% CI – 43‐83]; p<0.001). Main limitations Relatively small, clinical study, reliance on client questionnaire data, clients not blinded to the treatments the horse received, diet could have affected drug pharmacodynamics although mimics clinical practice and no validated scoring system available for glandular lesions. Conclusions These results suggest that gastric glandular disease does indeed result in clinical signs. In this population of horses, misoprostol was superior to omeprazole and sucralfate and warrants further evaluation in a large scale, multi‐centre trial.
- 26 February 2019
- Published by Wiley in Equine Veterinary Journal
- Vol. 51 (5) , 575-580
Misoprostol is superior to combined omeprazole‐sucralfate for the treatment of equine gastric glandular disease
Background Previous studies have demonstrated a poor response to healing of gastric glandular lesions with oral omeprazole and other medications. Objectives To evaluate the efficacy of two novel treatments (misoprostol [M] and combined omeprazole‐sucralfate [OS]) in the horse for gastric glandular disease. Study design Prospective, clinical study. Methods Sixty‐three sports horses with grade >1/4 glandular disease were identified by gastroscopy. Horses received either 5 μg/kg of misoprostol per os BID one hour prior to feeding or a combination of 4 mg/kg enteric coated omeprazole per os SID and 12 mg/kg sucralfate per os BID where drugs were given one hour prior to feeding and sucralfate given 60 minutes after omeprazole; allocation was dependent upon centre. Gastroscopy was repeated at 28‐35 days. Evaluators of the gastroscopy images were blinded to the treatments the horses received and images were reviewed independently. Results The most common presenting sign in both treatment groups was poor performance (Overall – 65.1%; M – 60.5% and OS – 75%). Overall healing (p<0.001; OR = 11 [2.8‐45]) and improvement (p = 0.006; OR = 11 [1.9‐59]) of lesions was associated with resolution of clinical signs. Misoprostol was shown to be superior to combined omeprazole‐sucralfate both for healing (M‐72% [95%CI–43‐67] and OS–20% [95% CI – 7‐41]; p<0.001) and improvement (M‐98% [95%CI–90‐100] and OS–65% [95% CI – 43‐83]; p<0.001). Main limitations Relatively small, clinical study, reliance on client questionnaire data, clients not blinded to the treatments the horse received, diet could have affected drug pharmacodynamics although mimics clinical practice and no validated scoring system available for glandular lesions. Conclusions These results suggest that gastric glandular disease does indeed result in clinical signs. In this population of horses, misoprostol was superior to omeprazole and sucralfate and warrants further evaluation in a large scale, multi‐centre trial.
- 12 June 2016
- Published by Wiley in Equine Veterinary Journal
- Vol. 48 (4) , 532-533
Letter to the Editor: Equine Veterinary Journal's antimicrobial stewardship policy
See correspondence by Hughes and Jago et al . and article by Jago et al .
- 12 June 2016
- Published by Wiley in Equine Veterinary Journal
- Vol. 48 (4) , 532-533
Letter to the Editor: Equine Veterinary Journal's antimicrobial stewardship policy
See correspondence by Hughes and Jago et al . and article by Jago et al .